Lung Cancer Trial, Recruiting (NCT07610616)

Lung Cancer Trial, Recruiting NCT07610616 Sponsor: Guangzhou Institute of Respiratory Disease Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07610616 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years of age or older.
You must have a type of lung cancer called non-small cell lung cancer (NSCLC), from which special lab-grown tissue samples (called organoids) and certain immune cells have been collected and are available for testing.
You are currently receiving or are planned to receive a cancer treatment drug called Trastuzumab deruxtecan (T-DXd), and you meet the medical requirements for that treatment.
You must be willing and able to sign a consent form agreeing to take part in the trial.
Your lab-grown tissue samples must show either strong or weak levels of two specific proteins (called HER2 and TROP2), as this determines which group of the trial you would be placed in (confirm with trial site).

Who may not be able to join:

You have a different type of lung cancer called small cell lung cancer (SCLC), confirmed by a tissue test.
The required lab-grown tissue samples or immune cells from your blood or tumor are not available for testing.
You have a medical reason that means you cannot safely receive the T-DXd treatment.
You have other serious health conditions that mean your life expectancy is estimated to be less than 3 months.
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07610616

Sponsor: Guangzhou Institute of Respiratory Disease

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT07610616

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years of age or older.
You must have a type of lung cancer called non-small cell lung cancer (NSCLC), from which special lab-grown tissue samples (called organoids) and certain immune cells have been collected and are available for testing.
You are currently receiving or are planned to receive a cancer treatment drug called Trastuzumab deruxtecan (T-DXd), and you meet the medical requirements for that treatment.
You must be willing and able to sign a consent form agreeing to take part in the trial.
Your lab-grown tissue samples must show either strong or weak levels of two specific proteins (called HER2 and TROP2), as this determines which group of the trial you would be placed in (confirm with trial site).

Who may not be able to join:

You have a different type of lung cancer called small cell lung cancer (SCLC), confirmed by a tissue test.
The required lab-grown tissue samples or immune cells from your blood or tumor are not available for testing.
You have a medical reason that means you cannot safely receive the T-DXd treatment.
You have other serious health conditions that mean your life expectancy is estimated to be less than 3 months.
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Guangzhou Institute of Respiratory Disease

Registry

ClinicalTrials.gov

Start date

28 December 2025

Est. completion

1 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Changes in ATP assay of tumor patient-derived organoids (PDOs) under treatment with ADCs and various drug combinations; Real-time high-content imaging reveals efficient internalization of pHrodo-conjugated ADCs; Integrated analysis of ADC IC50 determination and scRNA-seq data post co-culture; Multiplex immunofluorescence (mIF) and high-sensitivity Olink proteomics for inflammatory cytokines.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov